PMID: 9169959Jun 1, 1997Paper

A multicenter, double-blind comparison of the effects of nefazodone and fluoxetine on sleep architecture and quality of sleep in depressed outpatients

Journal of Clinical Psychopharmacology
R ArmitageA John Rush

Abstract

This study was an 8-week, randomized, double-blind, parallel-group investigation that compared the effects of nefazodone and fluoxetine on sleep architecture and on clinician- and patient-rated sleep measures in 43 outpatients with moderate to severe, nonpsychotic major depressive disorder and insomnia. Twenty-two patients received nefazodone 200 mg daily for 1 week, followed by 400 mg daily for 7 weeks. Twenty-one patients received fluoxetine 20 mg daily. Dosage increases (to 500 mg/day for nefazodone and 40 mg/day for fluoxetine) were available after day 29, depending on clinician judgement. Sleep parameters were measured during baseline phase, while patients were unmeasured and symptomatic, and at weeks 2, 4, and 8 of treatment. Nefazodone and fluoxetine were equally effective as antidepressants. However, compared with baseline, nefazodone increased sleep efficiency and reduced the number of awakenings and percent awake and movement time, whereas fluoxetine increased the number of awakenings and did not significantly alter sleep efficiency or percent awake and movement time. Although fluoxetine increased stage 1 sleep and rapid eye movement (REM) latency and reduced total percent REM sleep, nefazodone increased REM sleep, de...Continue Reading

References

May 15, 1992·Biological Psychiatry·A L SharpleyP J Cowen
Jan 1, 1990·Neuroscience and Biobehavioral Reviews·G W VogelA Hennessey
May 1, 1986·Psychiatry Research·A J RushC Burns
Jan 1, 1983·Progress in Neuro-psychopharmacology & Biological Psychiatry·G W Vogel
Apr 1, 1995·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·R ArmitageA J Rush
Jun 1, 1994·The British Journal of Psychiatry : the Journal of Mental Science·K RickelsC Weise
Apr 1, 1994·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·R ArmitageH P Roffwarg
Apr 1, 1994·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·W A HendrickseA J Rush
May 1, 1996·Psychological Medicine·A J RushM H Trivedi
Feb 1, 1960·Journal of Neurology, Neurosurgery, and Psychiatry·M HAMILTON

❮ Previous
Next ❯

Citations

Jun 5, 1999·Depression and Anxiety·T A MellmanL Barza
Sep 25, 2001·Depression and Anxiety·A WinokurM P Szuba
Mar 15, 2005·General Hospital Psychiatry·Michael E Thase
Apr 6, 2004·Sleep Medicine Reviews·Ripu D Jindal, Michael E Thase
Jan 27, 2006·International Clinical Psychopharmacology·Raymond W Lam
Nov 11, 1998·The American Journal on Addictions·S P HamiltonE V Nunes
Mar 23, 2006·Seminars in Dialysis·Ambreen GulEdwin M Trayner
Jan 1, 2010·Primary Care Companion to the Journal of Clinical Psychiatry·Michael E ThaseAnke Post
Mar 6, 2007·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Michael KlugeAxel Steiger
Apr 16, 2004·Alcoholism, Clinical and Experimental Research·Carlos A Hernandez-AvilaHenry R Kranzler
Feb 2, 2011·Depression and Anxiety·Nadia IovienoAndrew A Nierenberg
Jan 6, 2005·Archives of Medical Research·Reyes Haro, René Drucker-Colín
Dec 22, 2004·Progress in Neuro-psychopharmacology & Biological Psychiatry·Michael H WiegandRalph Schreiner
Jul 25, 2006·The American Journal of Geriatric Pharmacotherapy·Kevin T Bain
Jun 15, 2015·Seminars in Pediatric Neurology·Matthew M Troester, Rafael Pelayo
Feb 13, 2003·The Neuroscientist : a Review Journal Bringing Neurobiology, Neurology and Psychiatry·James ShafferyRoseanne Armitage
Jan 1, 1999·International Journal of Psychiatry in Clinical Practice·R Armitage
Sep 1, 2002·Expert Review of Neurotherapeutics·Rachel H Sharpe, John C Voris
Jul 23, 2003·Journal of Psychopharmacology·B RijnbeekJ M A van Gerven
Feb 24, 2018·Frontiers in Pediatrics·Mari S GolubChristoph W Turck
Sep 24, 2004·Psychosomatic Medicine·Rachel D WellsStephen P Duntley
Oct 18, 2005·Human Psychopharmacology·Andrew G Mayers, David S Baldwin
Jul 9, 2008·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Seithikurippu R Pandi-PerumalDaniel P Cardinali
Oct 3, 2002·The Journal of Nervous and Mental Disease·Daniel J Safer
Jan 6, 2001·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·R Armitage
May 7, 2004·Depression and Anxiety·Aimee L McRaeWendy Bayles-Dazet
Dec 20, 2013·The Cochrane Database of Systematic Reviews·Laura R MagniCorrado Barbui

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.